This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alran, S. Articles by Sigal-Zafrani, B. Search for Related Content PubMed PubMed Citation Articles by Alran, S. Articles by Sigal-Zafrani, B.

Validation and Limitations of Use of a Breast Cancer Nomogram Predicting the Likelihood of Non–Sentinel Node Involvement After Positive Sentinel Node Biopsy

¹ Department of Surgical Oncology, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
² Department of Biostatistics, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
³ Department of Medical Imaging, Nuclear Medicine, Institut Curie, 26 rue d’Ulm, 75005 Paris, France
⁴ Department of Pathology, Institut Curie, 26 rue d’Ulm, 75005 Paris, France

Correspondence: Address correspondence and reprint requests to: Séverine Alran, MD; E-mail: severine.alran{at}curie.net

Background: Axillary lymph node dissection (ALND) for patients with positive sentinel lymph nodes (SLNs) is currently under discussion in the literature. The breast cancer nomogram (BCN), an online tool developed by the Memorial Sloan-Kettering Cancer Center (MSKCC), aims to predict the risk of positive non-SLN in SLN-positive patients. The purpose of this study was to test the accuracy of the nomogram on patients with macrometastatic and micrometastatic SLN-positive biopsy findings.

Methods: Patient characteristics, tumor pathology, and positive SLN characteristics were collected on 588 consecutive patients who underwent completion ALND. The MSKCC BCN tool was used to calculate risk of metastases for all 588 cases that included a subgroup of the 213 patients with SLN micrometastases. The BCN was performed for positive SLN biopsy findings regardless of the method of metastasis detection. Evaluation of the BCN was performed by the area under the curve method.

Results: The BCN applied to all 588 patients achieved an area under the receiver operating characteristic curve (ROC) of .724 (range, .677–.771) compared with .76 in the MSKCC study. When the tool was applied solely to micrometastases found by hematoxylin and eosin staining and metastases found by immunohistochemistry, the area under the ROC was .538 (range, .423–.653).

Conclusions: The MSKCC nomogram has been validated for all the patients having a metastatic SLN at the Institut Curie. However, this model was not reliably predictive for positive non–SLN in cases with micrometastic positive SLN.

Key Words: Breast cancer • Sentinel lymph node • Nomogram • Micrometastasis • Axillary metastases • Prediction

This article has been cited by other articles:

				H. S. Cody III and K. J. Van Zee Predicting Nonsentinel Node Metastases in Sentinel Node-Positive Breast Cancer: What Have We Learned, Can We Do Better, and Do We Need To? Ann. Surg. Oncol., November 1, 2008; 15(11): 2998 - 3002. [Full Text] [PDF]

				E. Poirier, L. Sideris, P. Dube, P. Drolet, and S. H. Meterissian Analysis of Clinical Applicability of the Breast Cancer Nomogram for Positive Sentinel Lymph Node: The Canadian Experience Ann. Surg. Oncol., September 1, 2008; 15(9): 2562 - 2567. [Abstract] [Full Text] [PDF]

				A. Iasonos, D. Schrag, G. V. Raj, and K. S. Panageas How To Build and Interpret a Nomogram for Cancer Prognosis J. Clin. Oncol., March 10, 2008; 26(8): 1364 - 1370. [Abstract] [Full Text] [PDF]

				E. J.T. Rutgers Sentinel Node Biopsy: Interpretation and Management of Patients With Immunohistochemistry-Positive Sentinel Nodes and Those With Micrometastases J. Clin. Oncol., February 10, 2008; 26(5): 698 - 702. [Abstract] [Full Text] [PDF]